Nankai Hospital in Tianjin, China, is to offer NeoStem’s adult stem cell treatment to patients suffering from arthritis and orthopaedic conditions.
“Offering NeoStem’s licensed technology in our hospital means patients with orthopaedic and arthritic conditions have the advantage of using their body’s own cells for self-regeneration,” said Nankai Hospital president Dr Li Ping.
NeoStem is an international biopharmaceutical company with product and service revenues, global research and development capabilities.
Around 88 of the total 1,100 patient beds at the hospital are allocated to orthopaedic patients. Following the completion of a new hospital building, the number of orthopaedic beds is expected to rise to 1,000.